Ovarian cancer and smoking: individual participant meta-analysis including 28,114 women with ovarian cancer from 51 epidemiological studies.

Ovarian cancer and smoking: individual participant meta-analysis including 28,114 women with ovarian cancer from 51 epidemiological studies.

BACKGROUND: Smoking has been linked to mucinous ovarian cancer, but its effects on other ovarian cancer subtypes and on overall ovarian cancer risk are unclear, and the findings from most studies with relevant data are unpublished. To assess these associations, we review the published and unpublishe...

Bibliografski detalji
Glavni autori:	Beral, V, Gaitskell, K, Hermon, C, Moser, K, Reeves, G, Peto, R
Format:	Journal article
Jezik:	English
Izdano:	2012

Slični predmeti

Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls.
od: Beral, V, i dr.
Izdano: (2008)

Histological type as a predictor of ovarian cancer survival in the million women study
od: Hermon, C, i dr.
Izdano: (2018)

Histological subtypes of ovarian cancer associated with parity and breastfeeding in the prospective Million Women Study
od: Gaitskell, K, i dr.
Izdano: (2017)

Ovarian cancer survival by stage, histotype, and pre-diagnostic lifestyle factors, in the prospective UK Million Women Study
od: Gaitskell, K, i dr.
Izdano: (2021)

Tubal ligation and ovarian cancer risk in a large cohort: Substantial variation by histological type
od: Gaitskell, K, i dr.
Izdano: (2015)

Risk factors for ovarian cancer by histological phenotype in the Million Women Study
od: Gaitskell, K
Izdano: (2016)

Effect of smoking on different histotypes of kidney and urinary tract cancer in women
od: Gaitskell, K, i dr.
Izdano: (2018)

The epidemiology of epithelial ovarian cancer: a review
od: Banks, E, i dr.
Izdano: (1997)

The epidemiology of ovarian cancer
od: Beral, V
Izdano: (1980)

Ovarian cancer and hormone replacement therapy - Reply
od: Beral, V, i dr.
Izdano: (2007)

Sudden fall in breast cancer death rates in England and Wales.
od: Beral, V, i dr.
Izdano: (1995)

Ovarian cancer and hormone replacement therapy in the Million Women Study.
od: Beral, V, i dr.
Izdano: (2007)

False alarm: postmenopausal hormone therapy and ovarian cancer - Response
od: Beral, V, i dr.
Izdano: (2007)

Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients
od: Thompson ER, i dr.
Izdano: (2012-04-01)

Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies.
od: Cancer, C
Izdano: (2012)

Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies.
od: Collaborative Group on Epidemiological Studies of Ovarian Cancer
Izdano: (2012-01-01)

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer
od: Gaitskell, K, i dr.
Izdano: (2023)

Predictive value of RAD51 on the survival and drug responsiveness of ovarian cancer
od: Yuchen Feng, i dr.
Izdano: (2021-05-01)

Does smoking increase the risk of breast cancer? Reply
od: Beral, V, i dr.
Izdano: (2003)

Hormone replacement therapy and ovarian cancer.
od: Beral, V, i dr.
Izdano: (1991)

HORMONE REPLACEMENT THERAPY AND OVARIAN-CANCER
od: Beral, V, i dr.
Izdano: (1991)

Epidermal growth factor receptor blockers for the treatment of ovarian cancer
od: Morrison, J, i dr.
Izdano: (2018)

Does pregnancy protect against ovarian cancer?
od: Beral, V, i dr.
Izdano: (1978)

Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer
od: Michal M Hoppe, i dr.
Izdano: (2021-03-01)

lncRNA DDGC participates in premature ovarian insufficiency through regulating RAD51 and WT1
od: Duan Li, i dr.
Izdano: (2021-12-01)

Passive smoking and breast cancer in never smokers: prospective study and meta-analysis.
od: Pirie, K, i dr.
Izdano: (2008)

Subtypes of Ovarian Cancer and Ovarian Cancer Screening
od: Masafumi Koshiyama, i dr.
Izdano: (2017-03-01)

Psychological and Behavioral Impact of Participation in Ovarian Cancer Screening
od: Michael A. Andrykowski
Izdano: (2017-03-01)

Characterisation and development of 2448 and C51 : novel monoclonal antibodies targeting ovarian and breast cancer
od: Cua, Simeon
Izdano: (2017)

KIAA1529 regulates RAD51 expression to confer PARP inhibitors resistance in ovarian cancer
od: Yuan Qiao, i dr.
Izdano: (2022-10-01)

Risk factors for ovarian cancer: a case-control study.
od: Booth, M, i dr.
Izdano: (1989)

Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83?000 women with breast cancer from 16 countries.
od: Beral, V, i dr.
Izdano: (2004)

Reproductive factors and risk of ovarian cancer: a prospective study.
od: Kvåle, G, i dr.
Izdano: (1988)

An experimental model for ovarian cancer: propagation of ovarian cancer initiating cells and generation of ovarian cancer organoids
od: Yu-An Chen, i dr.
Izdano: (2022-09-01)

Mutation Analysis of the RAD51C and RAD51D Genes in High-Risk Ovarian Cancer Patients and Families from the Czech Republic.
od: Marketa Janatova, i dr.
Izdano: (2015-01-01)

Germline Mutational Landscape and Novel Targetable RAD51D Variant in Chinese Patients With Ovarian Cancer
od: Zheng Feng, i dr.
Izdano: (2024-06-01)

RAD51 as an immunohistochemistry-based marker of poly(ADP-ribose) polymerase inhibitor resistance in ovarian cancer
od: Yoo-Na Kim, i dr.
Izdano: (2024-04-01)

Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination
od: Jeremy Setton, i dr.
Izdano: (2021-10-01)

Clinical characteristics and survival analysis of Chinese ovarian cancer patients with RAD51D germline mutations
od: Hongwen Yao, i dr.
Izdano: (2022-12-01)

RAD51C germline mutations in breast and ovarian cancer cases from high-risk families.
od: Jessica Clague, i dr.
Izdano: (2011-01-01)